Tonmya demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT studyTreatment was well tolerated ...

Hanoi (VNA) - Prime Minister Pham Minh Chinh on October 20 signed a decision on the establishment of the National Steering ...

PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic ...

After 5 years, Kisqali ® plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive disease-free survival 1 Kisqali remains the only CDK4/6 inhibitor ...

Abstract: Accurate preoperative recurrence prediction for non-small cell lung cancer (NSCLC) is a challenging issue in the medical field. Existing studies primarily conduct image and molecular ...

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) PD-1 inhibitor Libtayo (cemiplimab-rwlc) as an adjuvant treatment for adult patients ...